Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 17;9:13495. doi: 10.1038/s41598-019-49756-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Injection of cMet Agonistic antibody in mice did not produce changes in the immune cell profile. After C57BL/6J wild-type mice were treated with cMet agonistic Ab (10 mg/kg, 20 mg/kg) or control IgG, their peripheral blood (Figure A-D) or spleens (Figure E-H) were harvested 2 hours later. Also we injected cMet agonistic Ab or control IgG under the same schedule as UUO experiment and their peripheral blood/spleens were harvested 7 days later. The different immune cell populations were enumerated by flow cytometry or an automated hematology analyzer. In the spleen cell suspensions, cMet treatment did not lead to obvious changes in the percentages of the CD3⁺ and CD25+ regulatory T cell populations (A,E), CD3+CCD44+ effector T cell populations (B,F), CD3+CCD25+CD44+ effector T cell populations (C,G), or CD11b+Gr-1+ myeloid (nonlymphoid) cell populations (D,H) compared with those in the control IgG treatment group. (I) Pro-inflammatory cytokines expression (IL-6, TNFα, IFNγ) didn’t show difference between the spleen cells of control IgG or cMet Ab injected mice.